Kornimate/medical-research-clean huggingface dataset:
cisplatin, etoposide, and cyclophosphamide in treating patients with extensive-stage small cell lung cancer

Conditions: Lung Cancer

Summary: rationale: drugs used in chemotherapy, such as cisplatin, etoposide, and cyclophosphamide, work in different ways to stop tumor cells from dividing so they stop growing or die. combining more than one chemotherapy drug may kill more tumor cells. purpose: this phase ii trial is studying how well giving cisplatin, etoposide, and cyclophosphamide together works in treating patients with extensive-stage small cell lung cancer.

objectives: primary * determine the safety of cisplatin, etoposide, and cyclophosphamide in patients with extensive stage small cell lung cancer. * determine the effect of this regimen on circulating endothelial cells in the peripheral blood of these patients. secondary * determine progression-free survival, tumor response rate, and overall survival in patients treated with this regimen. outline: this is a multicenter study. * induction therapy: patients receive cisplatin iv over 30 minutes-2 hours on day 1, etoposide iv over 1-2 hours on days 1-3 or etoposide iv on day 1 and orally twice daily on days 2-3, and oral cyclophosphamide twice daily on days 8-19. treatment repeats every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity. * maintenance therapy: patients receive oral cyclophosphamide twice daily in the absence of disease progression. patients are followed every 3 months for 2 years, every 6 months for 3 years, and then annually thereafter. projected accrual: a total of 10 patients will be accrued for this study.

Eligibility criteria:
disease characteristics: * histologically or cytologically confirmed small cell lung cancer * extensive stage disease (i.e., disease beyond the hemithorax and cannot be encompassed safely by a tolerable radiation field) * measurable disease * concurrent cns metastases allowed provided patient remains asymptomatic * radiotherapy or surgery for uncontrolled symptoms allowed before study entry patient characteristics: age * 18 and over performance status * ecog 0-2 life expectancy * not specified hematopoietic * absolute neutrophil count ≥ 1,500/mm\^3 * platelet count ≥ 100,000/mm\^3 * hemoglobin ≥ 8 g/dl (transfusion allowed) hepatic * alt ≤ 2 times upper limit of normal (uln) * bilirubin ≤ 2 times uln renal * creatinine ≤ 1.5 mg/dl or * creatinine clearance ≥ 60 ml/min other * not pregnant or nursing * negative pregnancy test * fertile patients must use effective contraception * no other malignancy within the past year except adequately treated basal cell or squamous cell skin cancer prior concurrent therapy: biologic therapy * no prior biologic therapy chemotherapy * no prior chemotherapy endocrine therapy * concurrent corticosteroids for brain metastases allowed radiotherapy * see disease characteristics * prior radiotherapy to any symptomatic site allowed provided the target site(s) was not previously irradiated * no concurrent radiotherapy surgery * see disease characteristics

Keywords: extensive stage small cell lung cancer recurrent small cell lung cancer
periosteal electrical dry needling for knee osteoarthritis

Conditions: Knee Osteoarthritis

Summary: the purpose of this research is to treat patients with knee osteoarthritis (oa) with periosteal electric dry needling (pedn). it is also to determine the optimal "maintenance" regiment (i.e. maintenance treatments, one maintenance treatment every other month, or one maintenance treatment per month) required to maintain improvements in pain and function following pedn. physical therapists commonly use pedn to treat knee oa, and previous studies suggest that this treatment is useful for reducing pain and improving function in patients with osteoarthritis. however, an appropriate maintenance treatment strategy to maintain these outcomes is presently unknown.

patients with knee osteoarthritis will be randomized to receive periosteal electrical dry needling 1-2 treatments per week for 6 weeks (up to 10 sessions total) followed by either: 1. no maintenance treatments, 2. one maintenance treatment every other month or 3. one maintenance treatment per month.

Eligibility criteria:
inclusion criteria: 1. adult over the age of 18 years old: 2. report of knee pain of at least 2/10 per nprs (0---10 scale) for \>3 months 3. report of at least 3 of the following per altman et al. (1986) (sensitivity = 95% / specificity = 69%) 1. over 50 years of age 2. less than 30 minutes of morning stiffness 3. crepitus on active motion 4. bony tenderness 5. bony enlargement 6. no palpable warmth of synovium exclusion criteria: 1. report of red flags to manual physical therapy to include: hypertension, infection, diabetes, peripheral neuropathy, heart disease, stroke, chronic ischemia, edema, severe varicosities, tumor, metabolic disease, prolonged steroid use, fracture, ra, osteoporosis, severe vascular disease, malignancy, etc. 2. history of physical therapy, massage therapy, chiropractic treatment, or injections for knee pain in last 4 weeks. 3. history of a partial or total knee replacement on the painful lower extremity. 4. history of a surgical procedure on either lower extremity in last 12 months. 5. two or more positive neurologic signs consistent with nerve root compression, including any two of the following: 1. weakness involving a major muscle group of the lower extremity. 2. diminished patella or achilles tendon reflex 3. diminished or absent sensation to pinprick in lower extremity dermatome. 6. involvement in litigation or worker's compensation regarding knee pain. 7. any condition that might contraindicate the use of periosteal electric dry needling 8. the patient is pregnant.
gls4/rtv and taf drug-drug interaction

Conditions: Chronic Hepatitis B

Summary: the purpose of this study is to evaluate the drug-drug-interaction (ddi), pharmacokinetics (pk) and tolerability of gls4/rtv combined with taf in healthy subjects.

this is a 2-part study with each part is an open-label study in healthy adult subjects. total 28 subjects will be enrolled into the study and divided into 2 part (part a and part b), 14 subjects in each part. with each part, the subject will be receive study drug per the defined treatment periods.

Eligibility criteria:
inclusion criteria: * males or females, of any race, between 18 and 50 years of age, inclusive, at screening; * body mass index between 18.0 and 28.0 kg/m2, inclusive, at screening; * females of childbearing potential and male subjects will agree to use contraception from screening to the 6 months after the last administration. exclusion criteria: * in the 12 months prior to screening, observing clinical significance of the following diseases, including but not limited to, gastrointestinal, kidney, liver, nerve, blood, endocrine, tumor, lung, immune, mental, or cardio-cerebrovascular diseases; * allergic constitution (multiple drug and food allergies); * a history of alcoholism; * take any prescription drug, over-the-counter drug, vitamin product or herbal medicine within 14 days of screening; * any drug that changes the liver enzyme activity, such as barbiturates and rifampicin, was taken within 30 days before screening; * p-gp, bcrp, oatp1b1, oatp1b3, oat1, oat3 or mrp4 inhibitors or inducers, such as azithromycin, pantoprazole or st. john's herb, etc., was taken within 30 days before screening; * female subjects are lactating or have positive blood pregnancy results during the screening period;
sunlight study: online support groups for ms to address covid-19

Conditions: MS (Multiple Sclerosis); COVID-19; Support Groups

Summary: stress and anxiety can have an adverse impact on health, and the experience of many around the 2020 outbreak of covid-19 is affecting health and well-being. individuals with chronic disease such as multiple sclerosis may be particularly vulnerable in some ways, but also particularly resilient in others. this study evaluates the effects of belonging to online support groups that meet weekly for 12 weeks to address the stress and anxiety felt by individuals with multiple sclerosis (ms). this study will also measure and explore the effects of online support groups.

anxiety is a pervasive and debilitating symptom for individuals with ms, who are at much greater risk for anxiety than the general population. the lifetime prevalence of anxiety in ms is estimated at 48.9%, compared to 37.9% in the general population. the negative consequences of anxiety for individuals with ms include impairment of work function and workplace attrition, increased healthcare usage and healthcare costs, increased physical disability (i.e., higher expanded disability status scale (edss) score), and reduced overall quality of life. and while anxiety has been shown to be acutely elevated both before and in the first years after diagnosis, individuals with longstanding ms also exhibit anxiety at higher rates than the general population. of note, women are at heightened risk for both anxiety and ms, and lower socioeconomic status (ses) is associated with increased prevalence of anxiety in ms. in the sunlight study, participants join a structured meeting in which they receive content specifically focused on anxiety, its detrimental impact on individuals with ms, and an emphasis on techniques to reduce anxiety. over the 12-week period of the intervention, participants learn techniques for stress reduction that can be self-administered, such that the benefits of participation outlive the active period of the intervention.

Eligibility criteria:
inclusion criteria: * ms diagnosis * 18 years or older exclusion criteria: * none
phase iii trial of concurrent chemotherapy alone in patients with low-risk nasopharyngeal carcinoma

Conditions: Nasopharyngeal Carcinoma

Summary: the purpose of this study is to compare concurrent chemoradiotherapy (ccrt) alone with induction chemotherapy (gemcitabine+cisplatin) plus ccrt in patients with low-risk locoregionally advanced nasopharyngeal carcinoma(npc).

patients with low risk npc( stage iii-iva, except t4n2/anytn3, ajcc 8th and ebv dna \<4000 copies/ml) are randomly assigned to receive ccrt alone or induction chemotherapy plus ccrt. patients in both groups receive cisplatin 100 mg/m² every 3 weeks for 3 cycles, concurrently with intensity-modulated radiotherapy (imrt). imrt is given as 2.12 gy per fraction with five daily fractions per week to a total dose of 70 gy. the induction chemotherapy plus ccrt group receive gemcitabine (1000 mg/m² d1,8) and cisplatin (80mg/m² d1) every 3 weeks for three cycles before ccrt. our primary endpoint is progress-free survival. secondary end points include overall survival (os), locoregional progression, distant progression and toxic effects. all efficacy analyses are conducted in the intention-to-treat population, and the safety population include only patients who receive their randomly assigned treatment.

Eligibility criteria:
inclusion criteria: 1. age 18-70 years old. 2. patients with newly histologically confirmed non-keratinizing (according to who histologically type). 3. tumor staged as iii-iva except t4n2/anytn3 (according to the 8th ajcc edition) and pretreatment plasm eb virus dna\<4000copies/ml. 4. ecog performance status less or equal to 1. 5. male and no pregnant female. 6. adequate marrow: leucocyte count ≥ 4000/μl, hemoglobin ≥ 90g/l and platelet count ≥ 100000/μl. 7. normal liver function test: alanine aminotransferase (alt), aspartate aminotransferase (ast) \< 1.5×upper limit of normal (uln) concomitant with alkaline phosphatase (alp) \< 2.5×uln, and bilirubin \< uln. 8. adequate renal function: creatinine clearance ≥ 60 ml/min. 9. patients must be informed of the investigational nature of this study and give written informed consent. exclusion criteria: 1. patients have evidence of relapse or distant metastasis. 2. who type keratinizing squamous cell carcinoma or basaloid squamous cell carcinoma. 3. treatment with palliative intent. 4. history of previous rt (except for non-melanomatous skin cancers outside intended rt treatment volume). 5. prior chemotherapy or surgery (except diagnostic) to primary tumor or nodes. 6. pregnancy or lactation (consider pregnancy test in women of child-bearing age and emphasize effective contraception during the treatment period). 7. prior malignancy except adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer. 8. any severe intercurrent disease, which may bring unacceptable risk or affect the compliance of the trial, for example, unstable cardiac disease requiring treatment, renal disease, chronic hepatitis, diabetes with poor control (fasting plasma glucose \> 1.5×uln), and emotional disturbance.

Keywords: nasopharyngeal carcinoma induction chemotherapy concurrent chemotherapy
impact of early respiratory rehabilitation in the exacerbations of re-admitted copd patients

Conditions: Pulmonary Disease, Chronic Obstructive

Summary: open clinical trial with 1 year follow up comparing the impact of an early respiratory rehabilitation program with the conventional respiratory rehabilitation in copd re-admitted patients. outcomes will be exacerbations, symptoms, functional capacity and quality of life related to health (hrqol).

open clinical trial with 1 year follow up comparing the impact of an early respiratory rehabilitation (err) program with the conventional respiratory rehabilitation (crr) in copd re-admitted patients. outcomes will be exacerbations, symptoms, functional capacity and quality of life related to health (hrqol). sixty patients will be randomized into the two groups: err starts the program during admission and continues at home immediately after discharge for a period of 3 months; crr was started at home one month after discharge from hospital and continues for 3 months. recruitment of patients and starting the rr program will occur in the first year. in the second year we will continue the intervention to those who have not completed the year. follow-up will last until the completion of the year of all patients.

Eligibility criteria:
inclusion criteria: * age\> 40 years * diagnostic criteria of copd gold ii-iv confirmed by spirometry * having frequent re-admissions (≥ 2 times / year). * sign the informed consent. exclusion criteria: * have completed a pulmonary rehabilitation program (including training) in the last 6 months. * respiratory and / or cardiac serious associated diseases. * end-stage copd (inability to perform exercises or treatment with morphine). * prognosis of \<6 months. * living in a residence or not having a primary caregiver. * cognitive disorders that prevent active participation. * patients who are admired to other hospitalization rooms than pneumology. * patients who do not belong to the area of health coverage of the respiratory rehabilitation home team

Keywords: early respiratory rehabilitation chronic obstructive pulmonary disease re-admitted patients open clinical trial exacerbations
treatment for sacroiliac joint pain using platelet-rich plasma (prp) versus steroid/anesthetic

Conditions: Low Back Pain; Sacroiliac Joint Synovitis

Summary: the purpose of this study is to determine if platelet-rich plasma is superior to steroid/anesthetic for the treatment of sacroiliac joint pain.

all patients with sacroiliac joint pain diagnosed by a back pain specialist will undergo physical examination maneuvers and a test lidocaine injection of the joint. patients who meet eligibility requirements will be randomized in a single-blind randomized controlled manner with a 50% chance of receiving platelet-rich plasma versus steroid/anesthetic injection of the sacroiliac joint(s).

Eligibility criteria:
inclusion criteria: * adult (\>18 y/o) males and females referred for therapeutic injection to the investigators spine interventional service by a physiatrist or pain anesthesiologist with a clinical diagnosis of sij pain confirmed by history * 50% or greater reduction in pain by a diagnostic anesthetic block using no more than 1.5 cc 2% lidocaine performed under imaging guidance by a pain interventionalist (pm\&r, pain anesthesia, or neuroradiology spine intervention). * baseline pain must be \>/=4 by numeric rating scale (nrs), at least 6 weeks in chronicity, and must not be multi-factorial (related to radiculopathy or axial pain localizing elsewhere) by physical examination or confounding medical history (infection, inflammatory spondyloarthropathy, or osseous metastatic disease). exclusion criteria: * sij steroid treatment within the prior 6 months. * patients with a history of infection currently on antibiotic therapy * usage of systemic immunosuppressants * pregnancy
combination of rituximab and nk immunotherapy for b lymphoma

Conditions: B-cell Lymphoma Recurrent

Summary: the aim of this study is the safety and efficacy of rituximab plus nk immunotherapy to recurrent b lymphoma.

by enrolling patients with b lymphoma adapted to enrolled criteria, this study will document for the first time the safety and the short and long term efficacy of the combined therapy using rituximab and natural killer (nk) cells. the safety will be evaluated by statistics of adverse reactions. the efficacy will be evaluated according to local relief degree, progress free survival (pfs) and overall survival (os).

Eligibility criteria:
inclusion criteria: * all standard therapies have failed according to nccn guidelines or the patient refuses standard therapies after cancer recurrence * body tumor 1-6, the maximum tumor length \< 5 cm * kps ≥ 70, lifespan \> 6 months * platelet count ≥ 80×109/l，white blood cell count ≥ 3×109/l, neutrophil count ≥ 2×109/l, hemoglobin ≥ 80 g/l exclusion criteria: * patients with cardiac pacemaker * patients with brain metastasis * patients with grade 3 hypertension or diabetic complication, severe cardiac and pulmonary dysfunction

Keywords: b lymphoma rituximab nk immunotherapy
a post market study evaluating the safety, device perfomance and possible emergent risks of celotres in preventing recurrence in keloid lesions treated adjunctive to surgical excision

Conditions: Earlobe Keloids

Summary: the objective of the study is to actively gather additional information on safety, device performance and possible emergent risks following the use of celotres in a post-market setting when used to reduce the recurrence rate, volume, appearance and/or symptoms associated with keloid scarring in subjects undergoing surgical excision of keloids as compared to the scientific literature.


Eligibility criteria:
inclusion criteria: * patients electing to undergo keloid excision procedure * patients able and willing to give written informed consent exclusion criteria: * patients with a known or potential risk of allergy or sensitivity to products or substances containing porcine gelatin.
a case control study to evaluate the cognitive and brain function of β-thalassemia patients.

Conditions: Thalassemia; Brain Function (Measured by ERP Level)

Summary: β-thalassemia syndromes are a group of hereditary disorders characterized by a genetic deficiency in the synthesis of beta-globin chains. in recent studies done in β-thalassemia major patients abnormal iron deposition was evident using mri in brain structures, cortex, putamen, and caudate nucleus . in most of the cases the neurological involvement is subclinical. cognitive functioning was evaluated in beta thalassemia major, compared with healthy controls, using a neuropsychological battery including tests of abstract reasoning, attention, executive functions, language, constructional/visuospatial skills, and memory. patients with beta thalassemia major, in particular those showing signs of hemosiderosis, had significantly impaired function in all neuropsychological tests. there was no relationship between cognitive performances and signs of deferoxamine toxicity, deferoxamine dosage, and levels of hemoglobin and ferritin. event-related potentials (erps) are one of the most informative and dynamic methods of monitoring the information stream in the living brain. erps are linked in time with a physical or mental event, and are typically extracted from the scalp-recorded electroencephalogram (eeg) by means of signal averaging. erps have been used in the assessment of cognitive function in several disorders, including anemia and iron deficiency anemia. however, literature regarding cognitive function and erp activity in thalassemia patients is extremely limited, especially in adults. the purpose of this study is to evaluate the cognitive and brain function in a group of 60 thalassemia patients and compare the results to healthy controls.


Eligibility criteria:
inclusion criteria: * thalassemia major and intermedia patients older than 6 years treated at emek medical center afula israel. * healthy controls matched for age and ethnicity. exclusion criteria: * patients suffering from acute diseases.

Keywords: blood transfusion hemosiderosis erp
ignite firefighters' health

Conditions: Cancer; Inflammation; Microbiome; Immune Function

Summary: investigators hope to learn about potential dietary intervention strategies (specifically a whole-food, plant-based diet) that may help lower cancer markers in firefighters.

the purpose of the san francisco (sf) firefighter's diet study is to determine if a diet low in processed foods, mostly plant-based, with added fermented foods, can lower the risk of cancer in firefighters. we will assess this by randomly assigning sf firefighters to either a whole-food, plant-based diet or their usual firehouse meals. participants will be followed for 12 weeks.

Eligibility criteria:
inclusion criteria: * age 18+ * active sf firefighter * willing to consume a plant-based diet (vegetables, fruit, whole grains, legumes, etc.) * willing to complete 4 clinic visits exclusion criteria: * weight \< 110 lb * bmi \>= 40 * self-reported uncontrolled hypercholesterolemia, hypertension or diabetes * pregnant, lactating, or planning to become pregnant during the course of the study. * use of any of the following drugs/supplements within the last 2 months: * systemic antibiotics, antifungals, antivirals, or antiparasitics (intravenous, intramuscular, or oral); * corticosteroids (intravenous, intramuscular, oral, nasal or inhaled); * cytokines; * methotrexate or immunosuppressive cytotoxic agents. * chronic, clinically significant, or unstable (unresolved, requiring ongoing changes to medical management or medication) pulmonary, cardiovascular, gastrointestinal, hepatic or renal functional abnormality, as determined by medical history, type 1 diabetes, dialysis * history of active cancer in the past 3 years except for squamous or basal cell carcinomas of the skin that have been medically managed by local excision * unstable dietary history as defined by major changes in diet during the previous month, where the subject has eliminated or significantly increased a major food group in the diet. * recent history of chronic excessive alcohol consumption defined as more than five 1.5-ounce servings of 80 proof distilled spirits, five 12-ounce servings of beer or five 5-ounce servings of wine per day; or \> 14 drinks/week. * any confirmed or suspected condition/state of immunosuppression or immunodeficiency (primary or acquired) including hiv infection, multiple sclerosis, and graves' disease. * surgery of the gi tract, with the exception of cholecystectomy and appendectomy, in the past five years. any major bowel resection at any time. * regular/frequent use of smoking or chewing tobacco, e-cigarettes, cigars or other nicotine-containing products * regular use of prescription opiate pain medication

Keywords: cancer inflammation microbiome immune function